Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway

NDA FilingSelinexor Plus RuxolitinibPositive

AI Analysis

Summary

Karyopharm plans to submit a supplemental NDA for selinexor plus ruxolitinib in myelofibrosis under the Accelerated Approval Pathway in August 2026, with priority review requested, based on compelling SVR35 and preliminary overall survival data.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

sNDA submission planned under Accelerated Approval Pathway based on SVR35 data and preliminary overall survival data

Importance:7/10

Sentiment:

0.70

sNDAAccelerated ApprovalPriority ReviewMyelofibrosisSVR35Overall Survival

Related Companies

$KPTI

Read the original article

Published by PR Newswire Pharma on July 30, 2026 8:06 PM

Read Original